Be a part of a polycythemia vera clinical trial

Consider joining the VERIFY study to learn more about an investigational study drug called rusfertide for polycythemia vera.

If you have received at least 3 phlebotomies in the last 6 months or at least 5 within in the last year for inadequate hematocrit control, you may qualify.

The VERIFY Study

Rusfertide, also called PTG-300, is an investigational medication. Study participation will help evaluate how safe and effective rusfertide is in keeping the hematocrit levels within the recommended range to reduce the need for phlebotomies.

Polycythemia Vera (PV)

The VERIFY study is a clinical trial for people with polycythemia vera (PV). PV is a type of myeloproliferative neoplasm (MPN) defined by the overproduction of red blood cells in the body, leading to a higher risk of blood clots. Click the button below to learn more about PV.

About PV

Study Clinic Locations

Contact a study location near you to see if you may qualify for the VERIFY clinical trial.

Contact a study clinic